证券代码：603193 证券简称：润本股份 公告编号：2025-026 润本生物技术股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.23元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/5/29 | － | 2025/5/30 | 2025/5/30 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 15 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本404,593,314股为基数，每股派发现金红利0.23 元（含税），共计派 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report highlights a steady recovery in social consumption, with April 2025 retail sales showing a year-on-year increase of 5.1%, and a total retail sales amount of 1618.45 billion yuan for the first four months of 2025, reflecting a 4.7% year-on-year growth [4][25] - The report suggests that the overall social consumption is expected to maintain stable growth due to effective policy measures aimed at boosting domestic demand, with a focus on the high-growth segments of gold jewelry and cosmetics [4][31] Summary by Sections Retail Market Overview - The retail industry index closed at 2110.59 points, down 1.61% for the week, underperforming the Shanghai Composite Index, which fell by 0.57% [6][15] - The jewelry sector showed the highest growth among retail segments, with a weekly increase of 7.56% and a year-to-date increase of 18.83% [17][20] Social Consumption Trends - In April 2025, the retail sales of consumer goods increased by 5.1%, driven by favorable consumption policies and the Qingming holiday effect [28][31] - Online retail sales for the first four months of 2025 reached 4741.9 billion yuan, growing by 7.7%, with physical goods online retail accounting for 24.3% of total retail sales [28][29] Investment Recommendations - Investment focus on high-growth segments under emotional consumption themes, particularly in gold jewelry and cosmetics [7][39] - Recommended companies in the gold jewelry sector include Laopuhuangjin, Chaohongji, and Zhou Dasheng, which are expected to benefit from differentiated product offerings and consumer insights [39][41] - In the cosmetics sector, recommended brands include Proya, Shangmei, and Juzi Biological, which are positioned to capitalize on the ongoing trend of domestic brand growth [39][41] Company Performance Highlights - Proya reported a 28.9% year-on-year increase in net profit for Q1 2025, driven by new product launches [40] - Chaohongji achieved a 25.4% year-on-year revenue growth in Q1 2025, indicating strong brand momentum [40] - Zhou Dasheng's revenue for Q1 2025 was down 47.3% year-on-year, highlighting challenges in the current market environment [40]

Core Viewpoint - The legal opinion confirms that the convening and conducting of the 2025 first extraordinary general meeting of shareholders by Runben Biotechnology Co., Ltd. complies with relevant laws and regulations, ensuring the legitimacy of the meeting and its resolutions [1][6]. Group 1: Meeting Procedures - The extraordinary general meeting was convened by the company's second board of directors based on a resolution from the eighth meeting held on May 6, 2025 [2][3]. - The meeting was held on May 22, 2025, at 15:30 in Guangzhou, and was presided over by the chairman Zhao Guiqin [2][3]. - The meeting's notice included details about the equity registration date, voting methods, and contact information, which were all in accordance with legal requirements [2][4]. Group 2: Attendance and Voting - A total of 6 shareholders and their representatives attended the meeting, holding shares registered with the Shanghai Stock Exchange as of the equity registration date of May 16, 2025 [3][4]. - Shareholders had the option to vote either in person or via an online voting platform provided by the Shanghai Stock Exchange, with specific time frames for each voting method [4][5]. - The online voting was validated by the Shanghai Stock Exchange system, and a total of 88 shareholders participated in online voting, representing 24,077,575 shares, which is 5.9510% of the total share capital [5]. Group 3: Resolutions Passed - The meeting adopted the proposal regarding the signing of the input-output regulatory agreement and external investment, with the voting results being consistent with the matters announced in the meeting notice [5][6]. - The voting process combined both in-person and online votes, ensuring that all votes were counted and reported accurately [6]. - The resolutions passed during the meeting were deemed legal and valid, adhering to the company's articles of association and relevant laws [6].

广东广信君达律师事务所 关于润本生物技术股份有限公司 2025 年第一次临时股东大会的法律意见书 致：润本生物技术股份有限公司 广东广信君达律师事务所（以下简称"本所"）接受润本生物技术股份有限公司（以下简 称"公司"）的委托，指派许丽华、马小希律师（以下简称"本律师"）出席了公司于 2025 年 5 月 22 日（星期四）下午 15:30 在广东省广州市天河区华夏路 28 号富力盈信大厦 40 楼公 司会议室召开的 2025 年第一次临时股东大会（以下简称"本次股东大会"），并依据《中华 人民共和国公司法》、《中华人民共和国证券法》、《上市公司股东会规则》、《上海证券交 易所股票上市规则》等中国现行法律、法规和其它规范性法律文件（以下合称"法律法规"） 以及《润本生物技术股份有限公司章程》（以下简称"公司章程"）的有关规定，就本次股东 大会的召集和召开程序、出席会议人员的资格和召集人资格、表决程序和表决结果等相关事宜 出具法律意见。 为出具本法律意见书，本律师听取了公司就有关事实的陈述和说明，审查了公司提供的相 关文件，包括但不限于： 1. 公司章程； 2. 第二届董事会第八次会议决议公告； 3. 公司于 ...

证券代码：603193 证券简称：润本股份 公告编号：2025-025 润本生物技术股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 22 日 (二)股东大会召开的地点：广东省广州市天河区珠江新城华夏路 28 号富力盈信 大厦 40 楼润本生物技术股份有限公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 94 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 320,894,275 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 79.3127 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，公司董事长赵贵钦先生主持。本次股东大 会采用现场投票和网 ...

Investment Rating - The investment rating for the light industry manufacturing sector is "Positive" [2] Core Insights - Overall consumer demand remains weak, but there are opportunities in specific segments where product and channel transformations can enhance market share, and brand recognition or performance recovery is expected [8] - The pet food segment shows high potential with strong consumer education barriers, brand loyalty, and significant single product effects [8] - The baby care market is fragmented, with strong brands rapidly increasing market share through cost-effectiveness and popular products, heavily relying on online sales [8] - Domestic second-tier brands in sanitary napkins and toothpaste are gaining market share, utilizing platforms like Douyin for marketing and channel empowerment [8] - The trend of innovative products and brand rejuvenation in the trendy toy sector is accelerating, with companies like Pop Mart and Blokus experiencing rapid revenue growth [8] Summary by Sections 1) Product & Channel Transformation - Baiya Co. reported a significant increase in revenue and is expected to see a gradual improvement in its profitability model [9] - Dengkang Oral Care's revenue growth exceeded expectations, with a sustainable improvement in profitability [9] - Runben Co. experienced strong revenue growth driven by new product launches, particularly in the sunscreen category [9] - Zhongchong Co. is successfully transforming its brand, with expectations of over 40% growth in its flagship product [9] - Companies in the trendy toy sector are well-positioned to benefit from consumer trends and new product launches [9] 2) High Competitive Barriers - Guibao Pet's revenue and profit growth exceeded expectations, driven by strong brand performance and successful high-end product launches [10] - The overall industry remains vibrant, with companies optimizing their product and channel structures [10] 3) Performance Recovery Expected - Chenguang Co. has underperformed due to a weak consumer environment, but recovery is anticipated if market conditions improve [10] - The company is focusing on enhancing its IP product strategy, which is expected to contribute to new growth points [10]

Investment Rating - The investment rating for the light industry manufacturing sector is "Positive" [2] Core Insights - Overall consumer demand remains weak, but there are opportunities in specific segments where product and channel transformations can enhance market share, and brand recognition or performance recovery is expected [2][8] - The pet food sector shows high potential with strong consumer education barriers, brand loyalty, and significant single product effects [2][8] - The baby care market is fragmented, with leading brands rapidly increasing market share through cost-effectiveness and popular products, heavily relying on online sales [2][8] - Domestic second-tier brands in sanitary napkins and toothpaste are gaining market share, utilizing platforms like Douyin for traffic generation and empowering other platforms and offline markets [2][8] - The trend of innovative products and brand rejuvenation in the trendy toy sector is accelerating, with companies like Pop Mart and Blokus experiencing rapid revenue growth [2][8] Summary by Sections 1) Product & Channel Transformation - Baiya Co. reported a significant revenue increase of 39% in Q4 2024 and 30% in Q1 2025, with a strong performance in e-commerce and a positive outlook for its probiotic series [3][9] - Dengkang Oral Care also showed robust growth, with a 39% increase in Q4 2024 and 19% in Q1 2025, benefiting from an optimized product structure and strong online sales [3][9] - Runben Co. experienced a 34% revenue increase in Q4 2024 and 44% in Q1 2025, driven by the rapid launch of new products [4][9] - The trendy toy sector, represented by companies like Blokus and Pop Mart, saw revenue growth of 156% and 278% respectively, indicating a strong market presence [4][9] 2) High Competitive Barriers - Guibao Pet's revenue and profit exceeded expectations, driven by strong growth in its proprietary brand and successful high-end product launches [10] - The overall industry remains buoyant, with companies optimizing product and channel structures, leading to sustained revenue growth and improved profitability [10] 3) Performance Recovery Expected - Chenguang Co. reported lower-than-expected performance due to a weak consumer environment, but recovery is anticipated if market conditions improve [10] - The company is focusing on enhancing its IP product strategy, which is expected to contribute to new growth points [10]

Meeting Details - The shareholders' meeting was held on May 15, 2025, at the company's office in Guangzhou, Guangdong Province [1] - The attendance rate of ordinary shareholders and preferred shareholders with restored voting rights was 78.5814% [1] Voting Process - The meeting was chaired by the company's chairman, Zhao Guiqin, and utilized a combination of on-site and online voting methods, complying with the Company Law and the company's articles of association [1] - The voting results for various proposals showed overwhelming support, with the majority of votes in favor [1][2] Proposal Outcomes - All non-cumulative voting proposals were approved, with A-share votes showing 99.9786% in favor for the first proposal [1] - Subsequent proposals also received similar support, with A-share votes consistently above 99.97% in favor [2] Legal Compliance - The meeting and voting procedures were confirmed to be in accordance with legal regulations and the company's articles of association, ensuring the validity of the resolutions passed [2]

Group 1 - The core viewpoint of the article is that the legal opinions regarding the 2024 annual shareholders' meeting of Runben Biotechnology Co., Ltd. confirm that the meeting's procedures, participant qualifications, and voting results comply with relevant laws and regulations [1][8]. Group 2 - The shareholders' meeting is scheduled for May 15, 2025, at 15:00 in Guangzhou, and was convened by the company's board of directors based on a prior board meeting decision [2][3]. - A total of 7 shareholders and their representatives attended the meeting, holding shares registered as of May 9, 2025 [3]. - The meeting allowed for both on-site and online voting, with specific timeframes for each voting method clearly communicated to shareholders [4][5]. Group 3 - The online voting involved 80 shareholders representing 24,125,909 shares, accounting for 5.9630% of the company's total share capital [5]. - The voting results from both on-site and online methods were combined, and the meeting's resolutions were signed by the attending board members [8]. Group 4 - The legal opinions affirm that the meeting's convening, participant qualifications, voting procedures, and results are all valid and comply with the company's articles of association and applicable laws [6][8].

Core Viewpoint - The company is planning to expand its production and research capabilities by investing in a new research and production base in Guangzhou, which is part of its C2M supply chain strategy aimed at increasing market share and competitive advantage [4][6][7]. Group 1: Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on May 22, 2025, at 15:30 in Guangzhou [3]. - The meeting will include both on-site and online voting options for shareholders [3][4]. - The agenda includes signing an output input supervision agreement and discussing external investments [4][7]. Group 2: Investment Details - The company has acquired a land parcel (ZSCB-E3-4) of approximately 31,585 square meters for the new research and production base, which will be adjacent to another site (ZSCB-E3-3) [5][6]. - The planned investment for the new base is 600 million RMB, focusing on various functions including office, research, production, and employee facilities [6][7]. - The investment does not constitute a related party transaction or a significant asset restructuring as defined by regulations [7].